A new preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR) following a ...
A new study found that a novel mRNA-based therapy that targets a protein called RUNX1 may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR), a disease caused by a ...